--- title: Accelerating Biopharma R&D with Continuous Freeze-Drying description: Explore how RheaLyo™ continuous freeze-drying technology transforms biopharma R&D by reducing costs and time while enhancing efficiency. image: https://www.rheavita.com/hubfs/Not%20used/GMP%20Flex_%20Spin-Stopper%20Isolator%20(RH)-1.png --- false ![](https://www.rheavita.com/hubfs/Not%20used/GMP%20Flex_%20Spin-Stopper%20Isolator%20(RH)-1.png) Industry brief ## Accelerating Biopharma R&D with Continuous Freeze-Drying [ Back ](https://www.rheavita.com/news) Accelerating Biopharma R&D with Continuous Freeze-Drying 5:51 ### Revolutionizing Lyophilization in Biopharma The biopharmaceutical industry is continually seeking innovative solutions to enhance efficiency and reduce costs in drug development. One of the most significant advancements in recent years is the RheaLyo™ continuous freeze-drying technology. This innovative approach promises to revolutionize lyophilization, a critical step in the manufacturing of stable biologic parenteral drug products. Unlike traditional batch freeze-drying, which is time-intensive and costly, RheaLyo™ offers a controlled, continuous process that significantly accelerates time-to-market and reduces expenses. ### The Economic Impact of Traditional Freeze-Drying Traditional lyophilization, while effective, has significant economic drawbacks. The process development and manufacturing phases represent a substantial portion of the biopharma R&D budget. Estimates suggest that the median capitalized research and development cost per drug product is around $1.1 billion, with formulation development and lyophilization contributing meaningfully to this figure. The complexity and time-intensive nature of traditional batch freeze-drying create challenges for scale-up and technology transfer, often requiring numerous trial and error runs. This approach not only disrupts pipeline progression but also hinders more profitable and efficient manufacturing. The economic burden is further exacerbated by the need for detailed determination of heat and mass transfer characteristics, which vary across different equipment scales.   ### Advantages of the RheaLyo™ Methodology RheaLyo™ continuous freeze-drying technology addresses many of the inefficiencies of traditional lyophilization. By employing a continuous and controlled spin-freezing and drying approach, RheaLyo™ optimizes the lyophilization process at the individual vial level. This method ensures uniformity and consistency, regardless of the number of vials processed. One of the standout features of RheaLyo™ is its ability to significantly reduce the time and materials required during formulation development. Traditional methods might take 4-7 weeks and consume large quantities of active pharmaceutical ingredients (APIs). In contrast, the RheaLyo™ methodology can complete this process in a matter of days, using substantially less API, thereby accelerating the overall development timeline.   ### Cost Savings and Efficiency in Scale-Up Scaling up production is one of the most challenging and costly aspects of biopharmaceutical manufacturing. Traditional batch freeze-drying requires revalidation of the freeze-drying protocol with each scale-up, leading to significant time and material waste. The RheaLyo™ technology, however, operates on a scale-out principle rather than scale-up. This means that increasing production volumes is achieved by replicating the process rather than expanding batch size. Consequently, each vial follows the same path and process, ensuring consistency and eliminating the need for revalidation. The continuous nature of RheaLyo™ also means that the technology does not rely on heat exchange between shelves and vials, as in traditional methods. Instead, cooling is achieved by jetting cold gas directly onto the vials, resulting in highly efficient energy transfer. This approach simplifies the scale-up process and significantly reduces costs associated with engineering and validation activities.   ### Faster Time-to-Market Benefits Time-to-market is a critical factor in the competitive biopharmaceutical industry. The RheaLyo™ continuous freeze-drying technology offers substantial time savings across various stages of drug development. From formulation to regulatory approval, RheaLyo™ accelerates each phase, providing a competitive edge. During the regulatory review process, continuous manufacturing applications have been shown to gain approval faster than batch applications. This expedited timeline can translate to significant early revenue benefits. Additionally, the consistency and reliability of the RheaLyo™ process reduce the effort required for regulatory dossiers, streamlining the approval process further.   ### Minimizing Risks and Regulatory Efforts In biopharmaceutical manufacturing, the risk of batch loss due to power outages or other disruptions is a significant concern. Traditional batch freeze-drying processes involve large volumes of product at risk simultaneously. In contrast, the RheaLyo™ technology processes a limited number of vials at a time, drastically reducing the potential impact of any single failure event. Moreover, the continuous production model of RheaLyo™ simplifies the regulatory submission process. Since the manufacturing process remains virtually unchanged throughout the drug development lifecycle, compiling regulatory dossiers becomes more straightforward. This consistency not only speeds up the dossier development but also makes it easier for regulatory agencies to review and approve applications.   ### Conclusion: The Future of Biopharma R&D The RheaLyo™ continuous freeze-drying technology represents a transformative advancement in biopharmaceutical manufacturing. By addressing the inefficiencies and high costs associated with traditional lyophilization, RheaLyo™ offers a faster, more cost-effective, and reliable solution. For biopharma companies looking to accelerate their R&D processes and bring drugs to market more swiftly, RheaLyo™ provides a compelling option. This innovative approach not only enhances operational efficiency but also delivers significant economic benefits, making it a valuable addition to any biopharmaceutical development strategy. [ Read the White Paper ](https://www.rheavita.com/white-papers)   ## Latests news ![](https://www.rheavita.com/hubfs/Bayer-wuppertal-1.jpeg) Industry brief #### What a Bayer Case Study Reveals About Continuous Freeze-Drying of Peptide Drug Products Read ![](https://www.rheavita.com/hubfs/AI-Generated%20Media/Images/The%20image%20depicts%20an%20empty%20glass%20vial%20as%20used%20for%20pharmaceutical%20products%20standing%20on%20a%20pile%20of%20books%20The%20books%20are%20guidelines%20for%20manufaturers%20An%20example%20is%20Annex%201-1.png) Industry brief #### Embracing Annex 1 Compliance with Advanced Freeze-Drying Read ![](https://www.rheavita.com/hubfs/Monza.jpg) News #### Patheon (Thermo Fisher Scientific) brings RheaVita’s continuous and controlled lyophilization technology to Monza site Read ![](https://www.rheavita.com/hubfs/Stoppered-1.png) News #### Top Pharmaceutical Freeze Drying Solution in Europe Read ![](https://www.rheavita.com/hubfs/Not%20used/GMP%20Flex_%20Spin-Stopper%20Isolator%20(RH)-1.png) Industry brief #### Accelerating Biopharma R&D with Continuous Freeze-Drying Read ![](https://www.rheavita.com/hubfs/site/website-pages/vial-with-jet-and%20red-beam_LinkedIn-optimized.jpg) Industry brief #### Innovative Spin-Freeze-Drying Technology Read ![](https://www.rheavita.com/hubfs/GMP%20Flex_%20Spin-Stopper%20Isolator%20(RH)-2.png) Industry brief #### Reimagining Batch Freeze-Drying: Scientific Solutions for Persistent Pain Points Read ![](https://www.rheavita.com/hubfs/AI-Generated%20Media/Images/The%20image%20features%20a%20stateoftheart%20BSL2%20laboratory-1.jpeg) News #### Launch of the BSL-2 compliant laboratory freeze-dryer Read ![](https://www.rheavita.com/hubfs/frost-window.jpg) News #### RheaVita joins lyoHUB Read ![](https://www.rheavita.com/hubfs/Generated%20Blog%20Post%20Images/Pharmaceutical%20manufacturing%20equipment%20showcasing.jpeg) Industry brief #### The Importance of Continuous Manufacturing Systems in Pharma Read Read more ![doctor-image](https://www.rheavita.com/hs-fs/hubfs/ReahVita-BV%20Images/Images/doctor-image.jpg?width=1500&height=1463&name=doctor-image.jpg) Our experts ### Schedule a consultation with our experts to explore the best solutions for your needs. [ Talk to an expert ](https://cta-eu1.hubspot.com/web-interactives/public/v1/track/click?encryptedPayload=AVxigLLyUe03lBe%2BivxKqBP6VfoSG2PKkR00Z4YMzgKmL4nbDGB4hb1xmMBeQe2KQ6IJMSreT7I3N2KcZSWvvdKG40Tit1yeQwTpJGVONH85tMTNrDJ%2BJ0hUUglQpnbUQQIDmTqN8r5pzbKkYYyIfp%2B%2FzMyK0ZLbnKMJ2AxEgXsI84LtmCrPYrd%2BN4%2FBzOdvWmI3&portalId=25028350) ## Discover our services The only commercially available controlled, continuous GMP-ready freeze-drying solution for precious biologics. ![flow-icon1](https://info.rheavita.com/hubfs/ReahVita-BV%20Images/Images/flow-icon1.svg) #### Feasibility studies Discover ![flow-icon1](https://info.rheavita.com/hubfs/ReahVita-BV%20Images/Images/flow-icon1.svg) #### Feasibility studies Discover ![flow-icon1](https://info.rheavita.com/hubfs/ReahVita-BV%20Images/Images/flow-icon1.svg) #### Feasibility studies Discover All services #### Stay in the know. Unsubscribe at any time. Subscribe to our newsletter and be the first to know when something’s happening. ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Alain Segers", "url" : "https://www.rheavita.com/news/author/alain-segers" }, "dateModified" : "2026-01-23T15:42:36.729Z", "datePublished" : "2025-08-20T11:49:01.000Z", "headline" : "Accelerating Biopharma R&D with Continuous Freeze-Drying", "image" : [ "https://www.rheavita.com/hubfs/Not%20used/GMP%20Flex_%20Spin-Stopper%20Isolator%20(RH)-1.png" ], "mainEntityOfPage" : { "@id" : "https://www.rheavita.com/news/accelerating-biopharma-rd-with-continuous-freeze-drying", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://www.rheavita.com/hubfs/Rheavita_logo.png" }, "name" : " RheaVita BV" } } ```